COVID-19: CDC, FDA and CMS Guidance
This page includes AHA Today stories and other AHA content on coronavirus COVID-19 guidance from the CDC, FDA, and CMS.
Hospitalization rates for COVID-19 were nearly four times higher for black, and two times higher for Hispanic, Medicare beneficiaries than for white Medicare beneficiaries, according to data on COVID-19 cases and hospitalizations released by the Centers for Medicare & Medicaid Services.
FDA issues guidance on removed COVID-19 antibody tests; reporting potential medical device shortages
Clinical laboratories and health care providers should stop using any antibody tests on the Food and Drug Administration’s “removed” test list, evaluate prior results from the test and whether to retest the patient using an FDA-authorized test, the agency said.
CDC: Emergency department visits for life-threatening conditions declined in pandemic’s early months
A new study released by the Centers for Disease Control and Prevention shows emergency department visits dropped by 23% for heart attacks, 20% for strokes and 10% for hyperglycemic crises in first 10 weeks after the COVID-19 public health emergency declaration.
A study of the first 20,000 adults hospitalized with severe or life-threatening COVID-19 to receive convalescent plasma found the investigational therapy safe in this diverse group of patients, according to findings from the Food and Drug Administration’s Expanded Access Program for COVID-19…
The Centers for Disease Control and Prevention recently updated its health care facility operations guidance to reflect the current COVID-19 pandemic environment.
Black COVID-19 patients were more likely to be hospitalized than white patients in a Centers for Disease Control and Prevention study that looked at cases in metropolitan Atlanta.
The Food and Drug Administration announced a public-private partnership to advance COVID-19 diagnostics.
The Food and Drug Administration issued updated templates for laboratories and manufacturers requesting emergency use authorization for molecular diagnostic tests that screen asymptomatic individuals for SARS-CoV-2 or use pooled samples.
The Food and Drug Administration said chloroquine phosphate and hydroxychloroquine sulfate could reduce remdesivir's antiviral activity.
COVID-19 hospitalizations were six times higher and deaths 12 times more likely for patients with reported underlying health conditions compared with those with none, according to a new Centers for Disease Control and Prevention study.